During Q4, device company fundraising totaled $4.2bn; while in vitro diagnostic firms and research tools players raised $6.1bn.

AngioDynamics appoints president and CEO; MDMA announces new VP and general counsel; Wright Medical chief operating officer resigns; and more personnel news from around the industry.

The US market for infection control and biosafety products will see strong growth ahead as hospitals continue the battle against health care-associated infections with innovative products and services designed to prevent needlesticks, nosocomial infections, and the spread of antibiotic-resistant organisms.

Device financing dropped more than 40% to $714 million in Q1; Smith & Nephew’s $1.7 billion acquisition of ArthroCare overshadowed acquisitions. Diagnostics companies raised $568 million, a 34% increase over 2013’s final quarter; nonprofits provided assets to diagnostics firms in multiple licensing arrangements.